Forbes April 15, 2021
Amy Feldman

It’s hard to flawlessly churn out billions of doses of drugs – and we aren’t doing a great job of it. A Midas List VC pulled together a dream team that says it’s come up with a better, faster way.

It’s all come down to Pfizer and Moderna. With Johnson & Johnson’s “one-and-done” shot on pause, America’s race against the virus and its variants now relies on our ability to flawlessly manufacture hundreds of millions of doses of the new mRNA vaccines – at warp speed. And previous quality control issues at a Pfizer plant, on top of Emergent BioSolutions fiasco with the J&J vaccine, are a stark reminder that manufacturing medicine is not easy.

Robert Nelsen, the top biotech...

Today's Sponsors

Teladoc Health
Premier
TripleTree

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

HLTH

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health
A “Mohan Nair Interview” with Scott Kirsner, CEO and Co-Founder of Innovation Leader
The Urgent Need for Innovations in Care Delivery
Seven Companies Changing Healthcare with Technology
One Year Later: Atlantic Health System CEO Shares COVID Learnings, Innovations
Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation